Zheng Wei, Lan Xian-Jun, Qin Zhen-Juan, Yang Xin-Hu, Shi Zhan-Ming
The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, China.
Front Psychiatry. 2023 Feb 8;14:1111754. doi: 10.3389/fpsyt.2023.1111754. eCollection 2023.
This systematic review of randomized controlled trials (RCTs) was conducted to explore the therapeutic effects and safety of active low-frequency repetitive transcranial magnetic stimulation (LF-rTMS) versus sham LF-rTMS in children and adolescent patients with first-episode and drug-naïve (FEDN) major depressive disorder (MDD).
A systematic literature search was performed, and data were extracted by two independent researchers. The coprimary outcomes were study-defined response and remission.
A systematic search of the literature yielded 442 references, of which 3 RCTs (130 children and adolescents with FEDN MDD, 50.8% male, and mean age range from 14.5 to 17.5 years) met the inclusion criteria. Among the two RCTs (66.7%, 2/3) examining the effects of LF-rTMS on study-defined response and remission and cognitive function, active LF-rTMS was more efficacious than sham LF-rTMS in terms of study-defined response rate and cognitive function (all < 0.05) but not regarding study-defined remission rate (all > 0.05). No significant group differences were found with regard to adverse reactions. None of the included RCTs reported the dropout rate.
These findings preliminarily found that LF-rTMS could benefit children and adolescents with FEDN MDD in a relatively safe manner, although further studies are warranted.
本系统评价随机对照试验(RCT)旨在探讨主动式低频重复经颅磁刺激(LF-rTMS)与假刺激LF-rTMS相比,对首次发作且未使用过药物的儿童及青少年重度抑郁症(MDD)患者的治疗效果及安全性。
进行系统的文献检索,由两名独立研究人员提取数据。共同主要结局指标为研究定义的反应和缓解情况。
系统的文献检索得到442篇参考文献,其中3项RCT(130例首次发作且未使用过药物的儿童及青少年MDD患者,男性占50.8%,平均年龄范围为14.5至17.5岁)符合纳入标准。在两项研究LF-rTMS对研究定义的反应、缓解及认知功能影响的RCT中(66.7%,2/3),就研究定义的反应率和认知功能而言,主动式LF-rTMS比假刺激LF-rTMS更有效(均<0.05),但在研究定义的缓解率方面无差异(均>0.05)。在不良反应方面未发现显著的组间差异。纳入的RCT均未报告脱落率。
这些发现初步表明,LF-rTMS可能以相对安全的方式使首次发作且未使用过药物的儿童及青少年MDD患者获益,尽管仍需进一步研究。